Neonatal HSV: Difference between revisions

From IDWiki
(Updated Pathophysiology and added Management)
(: added Epidemiology)
Line 2: Line 2:
   
 
*See also [[Herpes simplex virus]]
 
*See also [[Herpes simplex virus]]
  +
  +
=== Epidemiology ===
  +
  +
*Risk of transmission is determined by maternal serostatus at time of maternal genital infection
  +
**Newly acquired
  +
***First-episode primary infection (mother has no serum antibodies to HSV-1 or -2 at onset): risk of transmission is about 60%
  +
***First-episode nonprimary infection (mother has a new infection with one HSV type in the presence of antibodies to the other type): risk of transmission is less than 40%
  +
**Recurrent (mother has pre-existing antibodies to the HSV type that is isolated from the genital tract): risk of transmission is less than 2%
   
 
===Pathophysiology===
 
===Pathophysiology===
Line 37: Line 45:
 
*Usually presents in the first or second week of life
 
*Usually presents in the first or second week of life
   
== Management ==
+
==Management==
   
* '''Disseminated disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 21 days
+
*'''Disseminated disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 21 days
** If CNS disease, repeat lumbar puncture at the end of therapy to document resolution of CSF parameters and ensure that PCR is negative
+
**If CNS disease, repeat lumbar puncture at the end of therapy to document resolution of CSF parameters and ensure that PCR is negative
* '''Localized CNS disease:''' same as for disseminated
+
*'''Localized CNS disease:''' same as for disseminated
* '''Localized skin, eye, and mouth disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 14 days
+
*'''Localized skin, eye, and mouth disease:''' high-dose [[Is treated with::acyclovir]] 60 mg/kg/day IV divided q8h for at least 14 days
** For eye involvement, consult and ophthalmologist to add topical trifluridine, idoxuridine, or vidarabine
+
**For eye involvement, consult and ophthalmologist to add topical trifluridine, idoxuridine, or vidarabine
   
 
==Prognosis==
 
==Prognosis==

Revision as of 20:43, 20 July 2020

Background

Epidemiology

  • Risk of transmission is determined by maternal serostatus at time of maternal genital infection
    • Newly acquired
      • First-episode primary infection (mother has no serum antibodies to HSV-1 or -2 at onset): risk of transmission is about 60%
      • First-episode nonprimary infection (mother has a new infection with one HSV type in the presence of antibodies to the other type): risk of transmission is less than 40%
    • Recurrent (mother has pre-existing antibodies to the HSV type that is isolated from the genital tract): risk of transmission is less than 2%

Pathophysiology

  • Generally acquired at time of delivery, though 5-8% may be congenital
  • Localized CNS infection is thought to occur by retrograde axonal transmission

Clinical Presentation

  • Incubation period 7 to 21 days post-partum, with range from birth to 6 weeks
  • Spectrum of disease from cutaneous to disseminated

Disseminated disease

  • 25% of cases
  • Sepsis syndrome that predominantly affects the liver, lungs, and CNS
    • May not have skin findings (25%)
    • CNS involved in 60-75%, causing meningoencephalitis
    • Can also affect larynx, trachea, esophagus, stomach, lower gastrointestinal tract, spleen, kidneys, pancreas, and heart
  • Later in the course of the disease, may develop elevated ALT/AST and direct bilirubin, as well as coagulopathy and thrombocytopenia
  • Usually presents in the first or second week of life
  • Should be considered in sepsis without bacterial cause and with liver dysfunction or coagulopathy

Localized CNS disease

  • 30% of cases
  • Usually presents in the second or third week of life
  • May not have cutaneous manifestations
  • Can cause seizures

Skin, eye, and mouth disease

  • 45% of cases
  • Localized to skin, eyes, and/or mouth
  • Usually presents in the first or second week of life

Management

  • Disseminated disease: high-dose acyclovir 60 mg/kg/day IV divided q8h for at least 21 days
    • If CNS disease, repeat lumbar puncture at the end of therapy to document resolution of CSF parameters and ensure that PCR is negative
  • Localized CNS disease: same as for disseminated
  • Localized skin, eye, and mouth disease: high-dose acyclovir 60 mg/kg/day IV divided q8h for at least 14 days
    • For eye involvement, consult and ophthalmologist to add topical trifluridine, idoxuridine, or vidarabine

Prognosis

  • Disseminated disease has 65% mortality if untreated, improves to 30% with treatment
  • With CNS disease, 80% have developmental problems
  • Prognosis much better with isolated cutaneous disease